Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

April 30, 2011

Conditions
OsteosarcomaEwing Sarcoma Family TumorsMalignant Fibrous HistiocytomaSarcoma, SynovialFibrosarcomaLeiomyosarcoma
Interventions
BIOLOGICAL

REOLYSIN®

REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.

Trial Locations (4)

10461

Montefiore Medical Center/Albert Einstein College of Medicine, The Bronx

48106

University of Michigan Medical School, Ann Arbor

55905

Mayo Clinic, Rochester

78229

Institute of Drug Development, Cancer Therapy Research Center, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oncolytics Biotech

INDUSTRY